Plus Therapeutics’ Rhenium (186Re) Obisbemeda Shows Encouraging Survival Benefits in Glioblastoma Trial, Shares Up ~19%
Plus Therapeutics’ Rhenium (186Re) Obisbemeda Shows Encouraging Survival Benefits in Glioblastoma Trial, Shares Up ~19%
Plus Therapeutics (PSTV) has announced the publication of promising Phase 1 clinical trial results for its investigational radiotherapeutic, Rhenium (186Re) Obisbemeda, in the prestigious medical journal Nature Communications. The treatment, designed for recurrent glioblastoma (GBM), demonstrated significant safety, tumor response, and improved survival rates compared to current standards of care.
- Patients receiving doses above 100 Gy had a median overall survival (OS) of 17 months, more than double the standard 8-month OS seen with conventional therapies.
- No dose-limiting toxicity was observed, and most reported adverse events were unrelated to the treatment.
- The median OS across all treated patients was 11 months, exceeding the survival benchmark for recurrent GBM.
- Tumor response correlated strongly with absorbed radiation dose, with some patients receiving up to 739.5 Gy without significant toxicity.
Glioblastoma is the most common and aggressive brain cancer, affecting approximately 15,000 people annually in the U.S. The standard treatment options offer limited survival benefits and severe side effects, leaving patients with few effective choices. Rhenium (186Re) Obisbemeda is designed as a targeted injectable radiotherapy, delivering high-dose radiation directly to tumors while minimizing damage to surrounding tissues.
Plus Therapeutics is currently enrolling patients in its Phase 2 ReSPECT-GBM trial, which is evaluating the treatment at leading medical centers. This study builds on the encouraging Phase 1 data and aims to further validate the therapy’s potential as a safer and more effective alternative to existing GBM treatments.
